New hope for stem cell transplant complication: drug trial targets Hard-to-Treat GVHD
NCT ID NCT05531786
First seen Nov 01, 2025 · Last updated Jun 09, 2026 · Updated 32 times
Summary
This study tests a drug called pacritinib for people with moderate to severe chronic graft-versus-host disease (cGVHD) that hasn't responded to at least two prior treatments. cGVHD is an immune system problem that can occur after a stem cell transplant, causing damage to multiple organs. Participants take pacritinib capsules daily for 6 to 12 months, with regular checkups to monitor safety and effectiveness. The goal is to find a better treatment option for this serious condition.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GRAFT VS HOST DISEASE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
National Institutes of Health Clinical Center
RECRUITINGBethesda, Maryland, 20892, United States
Contact Phone: •••-•••-••••
-
University of Miami
RECRUITINGMiami, Florida, 33101, United States
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.